Ngā hua rapu kaituhi

1

Alternative Antigen Processing for MHC Class I: Multiple Roads Lead to Rome mā ClÃ¡udia C. Oliveira, Thorbald van Hall

I whakaputaina 2015

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
2

TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class Ilow cancers mā Koen A. Marijt, Elien M. Doorduijn, Thorbald van Hall

I whakaputaina 2018

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
3

The NKG2A–HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment mā Linda Borst, Sjoerd H. van der Burg, Thorbald van Hall

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
4

Future Challenges in Cancer Resistance to Immunotherapy mā Marit J van Elsas, Thorbald van Hall, Sjoerd H. van der Burg

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
5

The urgent need to recover MHC class I in cancers for effective immunotherapy mā Federico Garrido, Natalia Aptsiauri, Elien M. Doorduijn, Ángel M. García-Lora, Thorbald van Hall

I whakaputaina 2016

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
6

Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors mā Jim Middelburg, Kristel Kemper, Patrick Engelberts, Aran F. Labrijn, Janine Schuurman, Thorbald van Hall

I whakaputaina 2021

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
7

Immune Escape of Tumors in Vivo by Expression of Cellular Flice-Inhibitory Protein mā Jan Paul Medema, Joan de Jong, Thorbald van Hall, Cornelis J.M. Melief, Rienk Offringa

I whakaputaina 1999

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
8

Therapeutic cancer vaccines mā Cornelis J.M. Melief, Thorbald van Hall, Ramon Arens, Ferry Ossendorp, Sjoerd H. van der Burg

I whakaputaina 2015

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
9

Design of Agonistic Altered Peptides for the Robust Induction of CTL Directed towards H-2Db in Complex with the Melanoma-Associated Epitope gp100 mā Marianne J.B. van Stipdonk, Daniel Badia-Martinez, Marjolein Sluijter, Rienk Offringa, Thorbald van Hall, Adnane Achour

I whakaputaina 2009

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
10

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy mā Jan Willem Kleinovink, Koen A. Marijt, Mark J.A. Schoonderwoerd, Thorbald van Hall, Ferry Ossendorp, Marieke F. Fransen

I whakaputaina 2017

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
11

Differential Influence on Cytotoxic T Lymphocyte Epitope Presentation by Controlled Expression of Either Proteasome Immunosubunits or Pa28 mā Thorbald van Hall, Alice J.A.M. Sijts, Marcel Camps, Rienk Offringa, Cornelis J.M. Melief, Peter‐M. Kloetzel, Ferry Ossendorp

I whakaputaina 2000

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
12

Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling mā Koen A. Marijt, Marjolein Sluijter, Laura Blijleven, Sofie H. Tolmeijer, Ferenc A. Scheeren, Sjoerd H. van der Burg, Thorbald van Hall

I whakaputaina 2019

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
13

TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors mā Elien M. Doorduijn, Marjolein Sluijter, Bianca Querido, Cláudia C. Oliveira, Adnane Achour, Ferry Ossendorp, Sjoerd H. van der Burg, Thorbald van Hall

I whakaputaina 2016

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
14

The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma mā Mehrdad Talebian Yazdi, Sander van Riet, Annemarie van Schadewijk, Marta Fiocco, Thorbald van Hall, Christian Taube, Pieter S. Hiemstra, Sjoerd H. van der Burg

I whakaputaina 2015

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
15

CD4+ T Cell and NK Cell Interplay Key to Regression of MHC Class Ilow Tumors upon TLR7/8 Agonist Therapy mā Elien M. Doorduijn, Marjolein Sluijter, Daniela Salvatori, Serenella Silvestri, Saskia Maas, Ramon Arens, Ferry Ossendorp, Sjoerd H. van der Burg, Thorbald van Hall

I whakaputaina 2017

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
16

Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy mā Marieke F. Fransen, Mark J.A. Schoonderwoerd, Philipp Knopf, Marcel Camps, Lukas J.A.C. Hawinkels, Manfred Kneilling, Thorbald van Hall, Ferry Ossendorp

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
17

Cancer vaccines compensate for the insufficient induction of protective tumor-specific immunity of CD3 bispecific antibody therapy mā Jim Middelburg, Gaby Schaap, Marjolein Sluijter, Katy A. Lloyd, Vitalijs Ovcinnikovs, Janine Schuurman, Sjoerd H. van der Burg, Kristel Kemper, Thorbald van Hall

I whakaputaina 2025

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
18

CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory mā Hreinn Benonisson, Işıl Altıntaş, Marjolein Sluijter, Sandra Verploegen, Aran F. Labrijn, Danita H. Schuurhuis, Mischa Houtkamp, J. Sjef Verbeek, Janine Schuurman, Thorbald van Hall

I whakaputaina 2018

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
19

Monalizumab: inhibiting the novel immune checkpoint NKG2A mā Thorbald van Hall, Pascale André, Amir Horowitz, Dan Fu Ruan, Linda Borst, Robert Zerbib, Émilie Narni-Mancinelli, Sjoerd H. van der Burg, Éric Vivier

I whakaputaina 2019

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
20

Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy mā Marit J van Elsas, Camilla Labrie, Anders Etzerodt, Pornpimol Charoentong, Jordi J C van Stigt Thans, Thorbald van Hall, Sjoerd H. van der Burg

I whakaputaina 2023

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:

Ngā hua rapu - Thorbald van Hall

Alternative Antigen Processing for MHC Class I: Multiple Roads Lead to Rome mā ClÃ¡udia C. Oliveira, Thorbald van Hall

TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class Ilow cancers mā Koen A. Marijt, Elien M. Doorduijn, Thorbald van Hall

The NKG2A–HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment mā Linda Borst, Sjoerd H. van der Burg, Thorbald van Hall

Future Challenges in Cancer Resistance to Immunotherapy mā Marit J van Elsas, Thorbald van Hall, Sjoerd H. van der Burg

The urgent need to recover MHC class I in cancers for effective immunotherapy mā Federico Garrido, Natalia Aptsiauri, Elien M. Doorduijn, Ángel M. García-Lora, Thorbald van Hall

Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors mā Jim Middelburg, Kristel Kemper, Patrick Engelberts, Aran F. Labrijn, Janine Schuurman, Thorbald van Hall

Immune Escape of Tumors in Vivo by Expression of Cellular Flice-Inhibitory Protein mā Jan Paul Medema, Joan de Jong, Thorbald van Hall, Cornelis J.M. Melief, Rienk Offringa

Therapeutic cancer vaccines mā Cornelis J.M. Melief, Thorbald van Hall, Ramon Arens, Ferry Ossendorp, Sjoerd H. van der Burg

Design of Agonistic Altered Peptides for the Robust Induction of CTL Directed towards H-2Db in Complex with the Melanoma-Associated Epitope gp100 mā Marianne J.B. van Stipdonk, Daniel Badia-Martinez, Marjolein Sluijter, Rienk Offringa, Thorbald van Hall, Adnane Achour

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy mā Jan Willem Kleinovink, Koen A. Marijt, Mark J.A. Schoonderwoerd, Thorbald van Hall, Ferry Ossendorp, Marieke F. Fransen

Differential Influence on Cytotoxic T Lymphocyte Epitope Presentation by Controlled Expression of Either Proteasome Immunosubunits or Pa28 mā Thorbald van Hall, Alice J.A.M. Sijts, Marcel Camps, Rienk Offringa, Cornelis J.M. Melief, Peter‐M. Kloetzel, Ferry Ossendorp

Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling mā Koen A. Marijt, Marjolein Sluijter, Laura Blijleven, Sofie H. Tolmeijer, Ferenc A. Scheeren, Sjoerd H. van der Burg, Thorbald van Hall

TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors mā Elien M. Doorduijn, Marjolein Sluijter, Bianca Querido, Cláudia C. Oliveira, Adnane Achour, Ferry Ossendorp, Sjoerd H. van der Burg, Thorbald van Hall

CD4+ T Cell and NK Cell Interplay Key to Regression of MHC Class Ilow Tumors upon TLR7/8 Agonist Therapy mā Elien M. Doorduijn, Marjolein Sluijter, Daniela Salvatori, Serenella Silvestri, Saskia Maas, Ramon Arens, Ferry Ossendorp, Sjoerd H. van der Burg, Thorbald van Hall

Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy mā Marieke F. Fransen, Mark J.A. Schoonderwoerd, Philipp Knopf, Marcel Camps, Lukas J.A.C. Hawinkels, Manfred Kneilling, Thorbald van Hall, Ferry Ossendorp

Cancer vaccines compensate for the insufficient induction of protective tumor-specific immunity of CD3 bispecific antibody therapy mā Jim Middelburg, Gaby Schaap, Marjolein Sluijter, Katy A. Lloyd, Vitalijs Ovcinnikovs, Janine Schuurman, Sjoerd H. van der Burg, Kristel Kemper, Thorbald van Hall

Monalizumab: inhibiting the novel immune checkpoint NKG2A mā Thorbald van Hall, Pascale André, Amir Horowitz, Dan Fu Ruan, Linda Borst, Robert Zerbib, Émilie Narni-Mancinelli, Sjoerd H. van der Burg, Éric Vivier

Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy mā Marit J van Elsas, Camilla Labrie, Anders Etzerodt, Pornpimol Charoentong, Jordi J C van Stigt Thans, Thorbald van Hall, Sjoerd H. van der Burg

Ngā utauta rapu:

Ngā marau whai pānga